Abstract
The pharmacokinetics and pharmacodynamics of methylprednisolone were investigated after intravenous administration of methylprednisolone phosphate to healthy subjects at seven different doses (16 to 1000 mg). Forty different pharmacodynamic parameters were followed for 1 week. The pharmacodynamic data were analyzed as a function of time as well as cumulative effects in form of the areas under the effect–time curves. Statistically significant dose-dependent effects of methylprednisolone were observed for 15 pharmacodynamic parameters. Highly significant (P ≤ 0.0001) effects were increases in glucose levels, number of white blood cells, and segmented granulocytes as well as a decrease in the number of lymphocytes. For these pharmacodynamic effects an integrated pharmacokinetic/pharmacodynamic model was derived that translates the methylprednisolone plasma concentration–time profiles into effect– time profiles. This model allows prediction of pharmacodynamic effects for any single dose in the range studied at any time point.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
REFERENCES
H. Möllmann, P. Rohdewald, J. Barth, M. Verho, and H. Derendorf. Pharmacokinetics and dose linearity testing of methylprednisolone phosphate. Biopharm. Drug Dispos. 10:453–464 (1989).
H. Möllmann, P. Rohdewald, J. Barth, and H. Derendorf. Effect of high doses of glucocorticoids on the kinetics of human white blood cells in vivo. Med. Klin. 83:159–163 (1988).
A. S. Fauci. Mechanisms of corticosteroid action on lymphocyte subpopulations. II. Differential effects of in vivo hydrocortisone, prednisone and dexamethasone on in vitro expression of lymphocyte function. Clin. Exp. Immunol. 24:54–62 (1976).
A. S. Fauci and D. C. Dale. The effect of in vivo hydrocortisone on subpopulations of human lymphocytes. J. Clin. Invest. 53:240–246 (1974).
A. S. Fauci and D. C. Dale. The effect of hydrocortisone on the kinetics of normal human lymphocytes. Blood 46:235–243 (1975).
D. T. Kishi. In B. S. Katcher, L. Y. Young, and L. A. Koda-Kimble (eds.), Applied Therapeutics, 3rd ed., Applied Therapeutics, Spokane, WA, 1983, pp. 1275–1295.
F. D. Boudinot, R. D'Ambrosio, and W. J. Jusko. Receptor-mediated pharmacodynamics of prednisolone in the rat. J. Pharmacokin. Biopharm. 14:469–493 (1986).
B. Oosterhuis, R. J. M. Ten Berge, H. P. Sauerwein, E. Endert, P. T. A. Schellekens, and C. J. Van Boxtel. Pharmacokinetic-pharmacodynamic modeling of prednisolone-induced lymphocytopenia in man. J. Pharmacol. Exp. Ther. 229:539–545 (1984).
P. Rohdewald, J. Rehder, G. Drehsen, G. Hochhaus, H. Derendorf, and H. Möllmann. Simultaneous determination of glucocorticoid alcohols, their succinates and hydrocortisone in plasma. J. Pharm. Biomed. Anal. 3:565–573 (1985).
H. Derendorf. Pharmacokinetic evaluation of ß-lactam antibiotics. J. Antimicrob. Chemother. 24:407–414 (1989).
J. Limberg, M. LeBel, and H. Derendorf. Evaluation of free tissue concentrations of fleroxacin after oral administration. Pharm. Res. 7:422–424 (1990).
M. Gibaldi and D. Perrier. Pharmacokinetics, 2nd ed., Marcel Dekker, New York, 1982, pp. 84–88.
SAS/STAT, Version 6, SAS Institute Inc., Cary, NC.
N. H. G. Holford and L. B. Sheiner. Pharmacokinetic and pharmacodynamic modeling in vivo. CRC Crit. Rev. Bioeng. 5:273–322 (1981).
N. H. G. Holford and L. B. Sheiner. Understanding the dose-effect relationship: Clinical application of pharmacokinetic-pharmacodynamic models. Clin. Pharmacokin. 6:429–453 (1982).
Minsq Nonlinear Parameter Estimation, Version 2, MicroMath Scientific Software, Salt Lake City, UT.
S. M. Harding. Mode of action of glucocorticoids. Allergology 3:214–218 (1980).
P. Rohdewald, H. W. Möllmann, and G. Hochhaus. Affinities of glucocorticoids for glucocorticoid receptors in the human lung. Agents Actions 17:290–291 (1985).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Derendorf, H., Möllmann, H., Krieg, M. et al. Pharmacodynamics of Methylprednisolone Phosphate After Single Intravenous Administration to Healthy Volunteers. Pharm Res 8, 263–268 (1991). https://doi.org/10.1023/A:1015864709082
Issue Date:
DOI: https://doi.org/10.1023/A:1015864709082